Canaan Partners Ix LLC Arvinas, Inc. Transaction History

Canaan Partners Ix LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$36.01 - $74.24 $0 - $0	0 New	0 $0
Q1 2022 Apr 28, 2022	BUY	$60.27 - $81.57 $0 - $0	0 New	0 $0
Q4 2021 Feb 03, 2022	SELL	$65.85 - $96.21 $51.5 Million - $75.2 Million	-782,120 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $206 Million - $303 Million	-2,807,434 Reduced 78.21%	782,120 $64.3 Million
Q4 2020 Feb 02, 2021	SELL	$20.19 - $84.93 $8.08 Million - $34 Million	-400,000 Reduced 10.03%	3,589,554 $305 Million
Q3 2020 Oct 22, 2020	SELL	$22.99 - $36.34 $11.5 Million - $18.2 Million	-500,000 Reduced 11.14%	3,989,554 $94.2 Million
Q4 2019 Jan 27, 2020	BUY	$15.39 - $44.38 $69.1 Million - $199 Million	4,489,554 New	4,489,554 $184 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Canaan Partners Ix LLC, based on Form 13F filings with the SEC.

Stay updated on Canaan Partners Ix LLC with notifications on news.